TransTACs:novel heterobispecific antibodies for targeted protein degradation in cancer therapy  

作　　者：Wolfgang Walther Sebastian Torke Ulrike Stein 

机构地区：[1]Experimental and Clinical Research Center,Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine,Berlin,Germany [2]German Cancer Consortium(DKTK),Berlin and German Cancer Research Center(DKFZ),Heidelberg,Germany

出　　处：《Signal Transduction and Targeted Therapy》2024年第12期5370-5372,共3页信号转导与靶向治疗(英文)

摘　　要：In a recent article in Nature,Dingpeng Zhang and colleagues1 describe a novel approach for the degradation of target proteins.Their newly designed heterobispecific antibody modality hijacks the transferrin receptor internalization machinery on one hand and simultaneously marks a protein of interest(POI)for lysosomal degradation on the other.This structure therein constitutes a promising innovative addition to the rapidly evolving field of extracellular protein degradation in cancer drug development.

关 键 词：CANCER MODALITY ANTIBODIES 

分 类 号：R73[医药卫生—肿瘤]